Oxular is transforming the treatment of retinal disorders to improve patients’ vision. Oxular is developing a minimally invasive administration device for delivery of therapeutics to the suprachoroidal space of the eye and sustained release therapeutics for retinal diseases.
Oxular is a retinal therapeutics company which is developing treatments that can access specific small spaces within the eye to provide targeted drug distribution to tissues specifically involved in retinal diseases. This unique approach aims to increase therapeutics effectiveness, increase the duration of clinical effect and reduce side effects and complications from administration and minimise the frequency of dosing.
CEO
Thomas Cavanagh
Sub segment
Transcatheter aortic valve replacement
Location
Oxford, United Kingdom
